GlassScriptPhysician profile
Mohana R Arla
NPI 1710085600
$7,016.38
in general payments reported to CMS, 2019-2025
44 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $1,063 · 2021: $1,621 · 2022: $941 · 2023: $888 · 2024: $1,220 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,891.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,068.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $855.55 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Abbvie INC. | $843.27 | 2021-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $425.03 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $345.26 | 2020-2024 | Spravato |
| Novo Nordisk INC | $338.95 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $298.23 | 2019-2025 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.31 | 2019-2023 | Ofev, Tradjenta |
| Merck Sharp & Dohme LLC | $210.24 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $207.34 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $193.79 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $175.35 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.15 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $145.79 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $129.11 | 2020-2025 | Repatha, Repatha, Otezla |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohana Arla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.